Does the potential of a home run for Biogen with its Alzheimer's disease candidate outweigh the strong lineup and pipeline that Bristol-Myers Squibb offers?
News & Analysis: Biogen
Amgen, Biogen, and Gilead Sciences have each transformed their early investors.
Biogen’s victory in a patent case involving its blockbuster multiple sclerosis drug is positive, but other uncertainties are waiting in the wings.
We examine three biotech companies' past performances and future outlooks.
A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.
Investors cheered as the judge ruled in favor of Biogen in this long-awaited case.
A favorable patent ruling could translate to smoother sailing for Biogen's top-selling drug.
BIIB earnings call for the period ending December 31, 2019.
Share repurchases helped enhance the pharmaceutical giant's results.
Biogen handily beat expectations in the fourth quarter, but that doesn't mean this biotech stock is worth buying today.